デュピュイトラン拘縮：洞察・疫学・市場予測 (～2034年)

当レポートでは、世界の主要7カ国におけるデュピュイトラン拘縮の市場を調査し、疾患の背景・概要、疫学、治療と管理の概要、市場促進要因と障壁、アンメットニーズ、上市薬およびパイプライン薬のプロファイル、主要国の市場規模の推移・予測、競合情勢などをまとめ、最良の機会を発掘し、市場の潜在力を評価します。

対象地域

• 米国
• 欧州5カ国（ドイツ・フランス・イタリア・スペイン・英国）
• 日本

調査期間：2020年～2034年

レポートハイライト

• デュピュイトラン拘縮の市場は、疾患に対する認識の高まりと、医療支出の世界的増加により、今後数年間で変化を示すと考えられています。
• 企業や研究機関は、デュピュイトラン拘縮の研究開発に影響を与える可能性のある課題を分析し、その機会を探るべく取り組んでいます。開発中の治療薬は、病態を治療/改善するための新規アプローチに焦点を当てています。
• 大手企業はデュピュイトラン拘縮の治療薬の開発に取り組んでいます。新たな治療薬の上市は市場に大きな影響を与える見通しです。
• デュピュイトラン拘縮の新規治療薬の開発には、疾患病態のより深い理解が必要です。
• 当社の開発段階ごと（第III相および第II相）のパイプラインアセットに関する詳細な分析、さまざまな新興動向、詳細な臨床プロファイル、主なクロスコンペティション、発売日、製品開発活動を含むパイプライン薬の比較分析は、研究開発活動の全体的なシナリオを特定することで、治療ポートフォリオに関する意思決定プロセスにおいてクライアントを支援します。

目次

第1章 重要な洞察

第2章 デュピュイトラン拘縮：エグゼクティブサマリー

第3章 デュピュイトラン拘縮：競合分析

第4章 デュピュイトラン拘縮：市場概要

• 総市場のシェア (％) の分布：2020年
• 総市場のシェア (％) の分布：2034年

第5章 デュピュイトラン拘縮：疾患の背景・概要

• 兆候と症状
• 病態生理
• リスク因子
• 診断

第6章 ペイシェントジャーニー

第7章 デュピュイトラン拘縮：疫学・患者人口

• 疫学：主要調査結果
• 前提・根拠：主要7カ国
• 疫学シナリオ：主要7カ国
  • 主要7カ国におけるデュピュイトラン拘縮の疫学シナリオ：2020-2034年
• 疫学：米国
• 疫学：欧州5カ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 疫学：日本

第8章 治療アルゴリズム・現在の治療薬・医療行為

• デュピュイトラン拘縮の治療と管理
• デュピュイトラン拘縮の治療アルゴリズム

第9章 アンメットニーズ

第10章 デュピュイトラン拘縮治療の主なエンドポイント

第11章 上市製品

• 主要7カ国の上市製品リスト
• 医薬品名・企業名
  • 製品説明
  • 規制のマイルストーン
  • その他の開発活動
  • 重要臨床試験
  • 主要臨床試験の概要

第12章 新興治療薬

• 主なクロスコンペティション
• 医薬品名・企業名
  • 製品説明
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
  • 製品プロファイル

第13章 デュピュイトラン拘縮：主要7カ国市場の分析

• 主要調査結果
• 主要7カ国の市場規模
• 主要7カ国の市場規模：治療薬別

第14章 属性分析

第15章 主要7カ国：市場の展望

• 米国：市場規模
• 欧州5カ国：市場規模・展望
• ドイツ
• フランス
• イタリア
• スペイン
• 英国
• 日本市場の展望

第16章 デュピュイトラン拘縮：アクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightの能力

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Dupuytren's Disease Epidemiology (2020-2034)
• Table 2: 7MM Dupuytren's Disease Diagnosed and Treatable Cases (2020-2034)
• Table 3: Dupuytren's Disease Epidemiology in the United States (2020-2034)
• Table 4: Dupuytren's Disease Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Dupuytren's Disease Epidemiology in Germany (2020-2034)
• Table 6: Dupuytren's Disease Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Dupuytren's Disease Epidemiology in France (2020-2034)
• Table 8: Dupuytren's Disease Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Dupuytren's Disease Epidemiology in Italy (2020-2034)
• Table 10: Dupuytren's Disease Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Dupuytren's Disease Epidemiology in Spain (2020-2034)
• Table 12: Dupuytren's Disease Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Dupuytren's Disease Epidemiology in the UK (2020-2034)
• Table 14: Dupuytren's Disease Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Dupuytren's Disease Epidemiology in Japan (2020-2034)
• Table 16: Dupuytren's Disease Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Dupuytren's Disease Epidemiology (2020-2034)
• Figure 2: 7MM Dupuytren's Disease Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Dupuytren's Disease Epidemiology in the United States (2020-2034)
• Figure 4: Dupuytren's Disease Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Dupuytren's Disease Epidemiology in Germany (2020-2034)
• Figure 6: Dupuytren's Disease Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Dupuytren's Disease Epidemiology in France (2020-2034)
• Figure 8: Dupuytren's Disease Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Dupuytren's Disease Epidemiology in Italy (2020-2034)
• Figure 10: Dupuytren's Disease Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Dupuytren's Disease Epidemiology in Spain (2020-2034)
• Figure 12: Dupuytren's Disease Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Dupuytren's Disease Epidemiology in the UK (2020-2034)
• Figure 14: Dupuytren's Disease Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Dupuytren's Disease Epidemiology in Japan (2020-2034)
• Figure 16: Dupuytren's Disease Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Dupuytren's Disease - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Dupuytren's Disease, historical and forecasted epidemiology as well as the Dupuytren's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Dupuytren's Disease market report provides current treatment practices, emerging drugs, Dupuytren's Disease market share of the individual therapies, current and forecasted Dupuytren's Disease market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Dupuytren's Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Dupuytren's Disease Disease Understanding and Treatment Algorithm

The DelveInsight Dupuytren's Disease market report gives a thorough understanding of the Dupuytren's Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Dupuytren's Disease.

Treatment

It covers the details of conventional and current medical therapies available in the Dupuytren's Disease market for the treatment of the condition. It also provides Dupuytren's Disease treatment algorithms and guidelines in the United States, Europe, and Japan.

Dupuytren's Disease Epidemiology

The Dupuytren's Disease epidemiology division provide insights about historical and current Dupuytren's Disease patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Dupuytren's Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Dupuytren's Disease Epidemiology

The epidemiology segment also provides the Dupuytren's Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Dupuytren's Disease Drug Chapters

Drug chapter segment of the Dupuytren's Disease report encloses the detailed analysis of Dupuytren's Disease marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Dupuytren's Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Dupuytren's Disease treatment.

Dupuytren's Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Dupuytren's Disease treatment.

Dupuytren's Disease Market Outlook

The Dupuytren's Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Dupuytren's Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Dupuytren's Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Dupuytren's Disease market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Dupuytren's Disease market in 7MM.

The United States Market Outlook

This section provides the total Dupuytren's Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Dupuytren's Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Dupuytren's Disease market size and market size by therapies in Japan is also mentioned.

Dupuytren's Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Dupuytren's Disease market or expected to get launched in the market during the study period 2020-2034. The analysis covers Dupuytren's Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dupuytren's Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Dupuytren's Disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Dupuytren's Disease emerging therapies.

Reimbursement Scenario in Dupuytren's Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Dupuytren's Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dupuytren's Disease market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Dupuytren's Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Dupuytren's Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Dupuytren's Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Dupuytren's Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Dupuytren's Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dupuytren's Disease market

Report Highlights:

• In the coming years, Dupuytren's Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Dupuytren's Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Dupuytren's Disease. Launch of emerging therapies will significantly impact the Dupuytren's Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dupuytren's Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Dupuytren's Disease Report Insights

• Patient Population
• Therapeutic Approaches
• Dupuytren's Disease Pipeline Analysis
• Dupuytren's Disease Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Dupuytren's Disease Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Dupuytren's Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Dupuytren's Disease Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Dupuytren's Disease market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Dupuytren's Disease total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Dupuytren's Disease market size during the forecast period (2024-2034)?
• At what CAGR, the Dupuytren's Disease market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Dupuytren's Disease market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Dupuytren's Disease market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Dupuytren's Disease?
• What is the historical Dupuytren's Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Dupuytren's Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dupuytren's Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of Dupuytren's Disease during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Dupuytren's Disease treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Dupuytren's Disease in the USA, Europe, and Japan?
• What are the Dupuytren's Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Dupuytren's Disease?
• How many therapies are developed by each company for Dupuytren's Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Dupuytren's Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Dupuytren's Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dupuytren's Disease and their status?
• What are the key designations that have been granted for the emerging therapies for Dupuytren's Disease?
• What are the global historical and forecasted market of Dupuytren's Disease?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Dupuytren's Disease market
• To understand the future market competition in the Dupuytren's Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Dupuytren's Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Dupuytren's Disease market
• To understand the future market competition in the Dupuytren's Disease market

Table of Contents

1. Key Insights

2. Executive Summary of Dupuytren's Disease

3. Competitive Intelligence Analysis for Dupuytren's Disease

4. Dupuytren's Disease: Market Overview at a Glance

• 4.1. Dupuytren's Disease Total Market Share (%) Distribution in 2020
• 4.2. Dupuytren's Disease Total Market Share (%) Distribution in 2034

5. Dupuytren's Disease: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Dupuytren's Disease Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Dupuytren's Disease Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Dupuytren's Disease Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Dupuytren's Disease Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Dupuytren's Disease Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Dupuytren's Disease Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Dupuytren's Disease Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Dupuytren's Disease Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Dupuytren's Disease Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Dupuytren's Disease Treatment and Management
• 8.2. Dupuytren's Disease Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Dupuytren's Disease Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Dupuytren's Disease: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Dupuytren's Disease Market Size in 7MM
• 13.3. Dupuytren's Disease Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Dupuytren's Disease Total Market Size in the United States
  • 15.1.2. Dupuytren's Disease Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Dupuytren's Disease Total Market Size in Germany
  • 15.3.2. Dupuytren's Disease Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Dupuytren's Disease Total Market Size in France
  • 15.4.2. Dupuytren's Disease Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Dupuytren's Disease Total Market Size in Italy
  • 15.5.2. Dupuytren's Disease Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Dupuytren's Disease Total Market Size in Spain
  • 15.6.2. Dupuytren's Disease Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Dupuytren's Disease Total Market Size in the United Kingdom
  • 15.7.2. Dupuytren's Disease Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Dupuytren's Disease Total Market Size in Japan
  • 15.8.3. Dupuytren's Disease Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Dupuytren's Disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.